TrialDrug design, development and therapy2025

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study.

Hui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.